Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07737977

Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients

Sponsor: University Hospital, Montpellier

View on ClinicalTrials.gov

Summary

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

200

Start Date

2026-08

Completion Date

2029-08

Last Updated

2026-07-30

Healthy Volunteers

No

Interventions

OTHER

peripheral venous blood collection

collection of an additional 24 mL of blood following a routine blood draw

OTHER

collection of medical data related to patient care

collection of medical data from patient care during the 12-month follow-up period, drawn from electronic medical records, including laboratory test results, clinical examination findings, and paraclinical test results

Locations (2)

Montpellier University Hospital

Montpellier, Occitanie, France

Hospital Universitari Vall D'Hebron

Barcelona, Spain